Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03509012 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT03509012 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 105 participants.
The verdict
NCT03509012, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- DRUG Cisplatin (dose level 4)
- DRUG Cisplatin (dose level 3)
- DRUG Carboplatin (dose level 1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03509012
The ClinicalTrials.gov registry entry for NCT03509012 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Durvalumab is the first listed.
NCT03509012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03509012 about?
NCT03509012 is a clinical study titled "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors". This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
What is the current status of trial NCT03509012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2018-05-02. Estimated completion is 2025-01-08.
What interventions are being tested in trial NCT03509012?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Cisplatin (dose level 4) (DRUG), Cisplatin (dose level 3) (DRUG), Carboplatin (dose level 1) (DRUG).
Who is sponsoring clinical trial NCT03509012?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.